Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Acorda Therapeutics Announces Delisting from Nasdaq

Business Wire 2 days ago

Acorda Therapeutics Announces Nasdaq Delisting Notification

Business Wire April 3, 2024

Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement

Business Wire April 1, 2024

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

Business Wire April 1, 2024

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

Business Wire March 25, 2024

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Business Wire January 11, 2024

Acorda Therapeutics Reports Third Quarter 2023 Financial Results

Business Wire November 13, 2023

Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023

Business Wire November 6, 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®

Business Wire November 6, 2023

Acorda Therapeutics Reports Second Quarter 2023 Financial Results

Business Wire August 8, 2023

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: "For The Fighters(TM)"

Business Wire August 2, 2023

Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023

Business Wire August 1, 2023

Tom Burns Elected to the Acorda Therapeutics Board of Directors

Business Wire June 28, 2023

Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement

Business Wire June 26, 2023

Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split

Business Wire June 2, 2023

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split

Business Wire May 31, 2023

Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A

Business Wire May 30, 2023

Acorda Therapeutics Reports First Quarter 2023 Financial Results

Business Wire May 11, 2023

Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash

Business Wire May 10, 2023

Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

Business Wire May 8, 2023